News

In 90% of all scleroderma patients, gastrointestinal (GI) tract problems lead to uncomfortable and dangerous complications. Malnutrition, nausea, vomiting, and diarrhea are among the symptoms that plague GI tract-involved scleroderma patients. Understanding how these problems develop could lead to large gains in quality of life of affected patients and…

A new study entitled “Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study,” published in August issue of Annals of the Rheumatic Diseases, reports joint synovitis and tendon friction rubs can predict for early Systemic sclerosis progression. In this study,…

A new study entitled “Collagenous Colitis in Systemic Sclerosis: An Overlooked and Treatable Complication” published in Journal of Clinical Rheumatology highlights the possible occurrence of Collagenous Colitis with Systemic Sclerosis, and thus should be considered for therapeutic intervention by clinicians. Systemic sclerosis (SSc) is an autoimmune disease…

Scleroderma can often be a side effect of chronic graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation, as it occurs in 15.5% of chronic GVHD patients within five years. Patients are diagnosed with a condition known as sclerodermatous chronic GVHD (scGVHD) and are at…

A new study entitled “Vascular Receptor Autoantibodies in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis” published in the October issue of American Journal of Respiratory and Critical Care Medicine reports that vascular antibodies can be prognostic biomarkers in Systemic Sclerosis (SSc) associated with pulmonary arterial…

Rosa Johnson Scleroderma, an autoimmune disease, causes an abnormal toughening of the area of the body affected, which can be anywhere from the skin to internal organs, which leads to a steady loss of function. The Scleroderma Foundation estimates that about 300,000 Americans have scleroderma, and the disease is…

The chief executive officer of clinical stage biopharmaceutical company Corbus Pharmaceuticals Holdings, Yuval Cohen, Ph.D., is presenting an update on the company’s research, as well as revision of previous clinical developments regarding Corbus’s lead product candidate, Resunab, at the Leerink Partners Rare Disease Roundtable. The product candidate is being studied by the drug…

The Scleroderma Foundation announced that their national Board of Directors is merging the Southern California Chapter with the Greater San Diego Chapter, in order to increase the efficiency of their support and education programs. The merger was proposed by the chapters themselves and approved by the board, and the…

Having previously experimented with the use of Viagra (Sildenafil) as a possible therapy for Pulmonary arterial hypertension (PAH), researchers have now evaluated the use of the drug in treating Systemic Sclerosis (SSc) in patients. SSc or scleroderma, is a chronic connective tissue disease characterized by hardening of the skin. The…

Scleroderma is a rare, chronic rheumatic disease, combined forms of which, including localized, systemic, and related conditions, affecting an estimated 300,000 Americans, primarily females who are 30 to 50 years old at onset. The overall occurrence of Scleroderma is 1 per 1,000 (.1% of the 310 million U.S. population)…